Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Remington

Showing results (61-70 of 410) with videos related to

Pageof 41
Sort By:
Schizophrenia (Heidelberg, Germany)|December 17, 2025
Antipsychotic discontinuation in schizophrenia: rational or reckless?Robert B Zipursky, Ofer Agid, Gary Remington
The Journal of Clinical Psychiatry|February 13, 2002
Hyperinsulinemia in psychiatric patients treated with olanzapineTony A Cohn, Gary Remington, Homa Kameh
Schizophrenia Research|May 9, 2006
Impact of haloperidol, a dopamine D2 antagonist, on cognition and moodHuma Saeedi, Gary Remington, Bruce K Christensen
Lancet (London, England)|December 10, 2013
Efficacy of antipsychotic drugs for schizophreniaCynthia O Siu, Ofer Agid, Gary Remington
The Lancet. Psychiatry|April 28, 2018
Improving outcomes in schizophrenia by preventing early relapsesRobert B Zipursky, Ofer Agid, Gary Remington
The Annals of Pharmacotherapy|July 1, 2010
Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gainMargaret K Hahn, Tony Cohn, Gary Remington
JAMA Psychiatry|May 7, 2015
Measuring the effects of treatment with antipsychoticsCynthia O Siu, Ofer Agid, Gary Remington
The American Journal of Psychiatry|March 5, 2008
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effectsMonica Hazra, David C Mamo, Gary Remington
Annals of the Academy of Medicine, Singapore|June 13, 2014
Schizophrenia: no health without physical healthJimmy Lee, Tih-Shih Lee, Gary Remington
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 23, 2010
Where to position clozapine: re-examining the evidenceOfer Agid, George Foussias, Shayna Singh, et al.
Pageof 41

Showing results (61-70 of 410) with videos related to

Sort By:
Pageof 41
Schizophrenia (Heidelberg, Germany)|December 17, 2025
Antipsychotic discontinuation in schizophrenia: rational or reckless?Robert B Zipursky, Ofer Agid, Gary Remington
The Journal of Clinical Psychiatry|February 13, 2002
Hyperinsulinemia in psychiatric patients treated with olanzapineTony A Cohn, Gary Remington, Homa Kameh
Schizophrenia Research|May 9, 2006
Impact of haloperidol, a dopamine D2 antagonist, on cognition and moodHuma Saeedi, Gary Remington, Bruce K Christensen
Lancet (London, England)|December 10, 2013
Efficacy of antipsychotic drugs for schizophreniaCynthia O Siu, Ofer Agid, Gary Remington
The Lancet. Psychiatry|April 28, 2018
Improving outcomes in schizophrenia by preventing early relapsesRobert B Zipursky, Ofer Agid, Gary Remington
The Annals of Pharmacotherapy|July 1, 2010
Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gainMargaret K Hahn, Tony Cohn, Gary Remington
JAMA Psychiatry|May 7, 2015
Measuring the effects of treatment with antipsychoticsCynthia O Siu, Ofer Agid, Gary Remington
The American Journal of Psychiatry|March 5, 2008
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effectsMonica Hazra, David C Mamo, Gary Remington
Annals of the Academy of Medicine, Singapore|June 13, 2014
Schizophrenia: no health without physical healthJimmy Lee, Tih-Shih Lee, Gary Remington
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 23, 2010
Where to position clozapine: re-examining the evidenceOfer Agid, George Foussias, Shayna Singh, et al.
Pageof 41